The role of selected neuropeptides in pathogenesis of atopic dermatitis.
BACKGROUND
Atopic dermatitis (AD) is an inflammatory skin disease of a chronic course. The role of neuropeptides in pathogenesis of this disorder is probably not crucial; however, there is evidence that these substances influence the development and course of AD.


OBJECTIVE
The aim of this study was to evaluate the plasma level of substance P, neuropeptide Y (NPY) and calcitonin gene related peptide (CGRP) in AD patients during exacerbation and remission of the disease.


METHODS
Forty-nine patients with AD, aged 17 to 56 years, participated in the study. Among this group, there were 25 males (51%) and 24 females (49%). The disease lasted from 1 to 55 years. The severity of the disease was assessed with SCORAD index. The severity of pruritus was evaluated with Visual Analog Scale and a specially designed questionnaire. Neuropeptides plasma level was detected with radioimmunoassay.


RESULTS
Substance P plasma level in AD patients during exacerbation and remission was significantly higher than in the control group. There was a negative correlation between substance P plasma level and total IgE level. CGRP plasma level during exacerbation of AD was significantly lower than in healthy controls and increased in the remission. Significantly higher CGRP concentration was observed in patients suffering from severe pruritus; however, both in patients with more and less severe pruritus, CGRP plasma level was lower than in controls. Higher CGRP plasma level was also observed in patients with more severe disease. NPY plasma level in patients with AD was significantly increased both during exacerbation and remission. During remission of AD, NPY concentration was higher than during exacerbation.
Salomon
J
J
Department of Dermatology, Venereology and Allergology, University of Medicine, Wroclaw, Poland. jsalomon@op.pl
Baran
E
E
D000293:Adolescent; D000328:Adult; D015740:Calcitonin Gene-Related Peptide / Q000097:blood / Q000502:physiology*; D016022:Case-Control Studies; D003876:Dermatitis, Atopic / Q000097:blood / Q000209:etiology* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007249:Inflammation / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood / Q000502:physiology*; D010147:Pain Measurement; D011537:Pruritus / Q000209:etiology / Q000503:physiopathology; D012720:Severity of Illness Index; D012867:Skin / Q000098:blood supply; D013373:Substance P / Q000097:blood / Q000502:physiology*
D009478:Neuropeptide Y; D013373:Substance P; D007073:Immunoglobulin E; D015740:Calcitonin Gene-Related Peptide